Petersdorf Effie W
Department of Medicine, University of Washington, 1959 Northeast Pacific, Seattle, WA 98195, USA.
Best Pract Res Clin Haematol. 2007 Jun;20(2):155-70. doi: 10.1016/j.beha.2006.09.001.
Consideration of potential donors for transplantation includes a rigorous assessment of the availability and HLA-match status of family members, and the identification of suitable unrelated donors when related donors are not available. Because HLA gene products provoke host-versus-graft and graft-versus-host alloimmune responses, HLA matching serves a critical preventive role in lowering risks of graft failure and graft-versus-host disease (GVHD). At the same time, graft-versus-leukemia effects associated with HLA mismatching may provide an immunological means to lower the recurrence of post-transplant disease in high-risk patients. The definition of a suitable allogeneic donor is ever changing, shaped not only by current typing technology for the known HLA genes but also by the specific transplant procedure. Increased safety of alternative donor hematopoietic cell transplantation (HCT) has been achieved in part through advances in the field of immunogenetics. Increased availability of HCT through the use of HLA-mismatched related and unrelated donors is feasible with a more complete understanding of permissible HLA mismatches and the role of NK-KIR genes in transplantation.
对潜在移植供体的评估包括对家庭成员的可用性和HLA匹配状况进行严格评估,以及在相关供体不可用时识别合适的无关供体。由于HLA基因产物会引发宿主抗移植物和移植物抗宿主同种免疫反应,HLA匹配在降低移植物失败和移植物抗宿主病(GVHD)风险方面起着关键的预防作用。同时,与HLA不匹配相关的移植物抗白血病效应可能为降低高危患者移植后疾病复发提供一种免疫手段。合适的异基因供体的定义一直在变化,这不仅受到已知HLA基因的当前分型技术的影响,还受到特定移植程序的影响。替代供体造血细胞移植(HCT)安全性的提高部分得益于免疫遗传学领域的进展。通过使用HLA不匹配的相关和无关供体来增加HCT的可用性是可行的,前提是对允许的HLA不匹配以及NK-KIR基因在移植中的作用有更全面的了解。